GNC is an incredibly irresponsible company for selling products while operating like a flea market. They don't even check if the products meet regulations are safe for consumers. Not to mention, when the FDA had warned them back in 2013 to stop selling products that were proven to be contaminated they ignored and continued selling. Not only did they continue selling but they put those products on sale with "buy out" to clear items from inventory. They don't care about people's health...sad for those who are now suffering.
Need to take into account the other wells. it is viable because management thinks the other wells will produce (bromine level indicators). They'll extract the bromine out after so this is very profitable.
Technical people should cue in to the fact that this brine has very concentrated bromine which means the other wells will produce as well. Cheers!
Takeda was minimizing risk since they had failed with Amylin. They are still pursuing a lifestyle drug so I suspect with sales success in the US and now EU approval, they will pursue a buyout of OREX for the rest of the world market. Some of the major western pharmas were sitting on the sideline to see if the latest obesity drugs could be approved and sold. I think contrave/mysimba is on their radar as well. All in all, very good partnership terms is in the works or a great buyout from Takeda.
With the EU and FDA approvals, other countries which are part of both agency's regulatory network will probably follow suit. OREX has a lot of leverage now for global licensing so a buyout would make sense before this happens. Cheers.
Wait for mainstream news to pick it up tomorrow morning in Europe. Scanning the news, you can see that some of the big papers haven't even published yet.
Essentially, invest in the obesity market...pick the top 2 drugs and you'll profit.
Diversify, buy Orex. there's no need to hate 1 drug or pick one over the other. The entire obesity market is growing...the quesiton is who's going to be the fastest grower?
Good exposure - JAMA Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity
Standing committee already occurred on Monday. Everyone's waiting for an official announcement. Which..takes 4 or more days to be published on the register.
There's a lot of history/safety data on estriol, and this dose is physiologically conservative. Analogues would need safety data so it is well behind in development. I speculate that most if not all MS drug companies will want a combo treatment with estriol. Benefits were rapid and if Voskuhl and SYN gets a neuroprotective claim then there's no reason not to. It will be interesting to hear about the bidding process.
Sorry, in layman's terms...estriol binds to mainly receptor B so these scientists are finding small molecules to solely bind to the same receptor. Their mice model shows strong evidence that there is repair. Expect great results form the scans.
Dr. Voskuhl's work is getting some early confirmation by another group working with analogues.
Multiple functional therapeutic effects of the estrogen receptor β agonist indazole-Cl in a mouse model of
"Interestingly, Ind-Cl acts somewhat like estrogen in the body, since it binds to specific estrogen receptors. Pregnant women with MS experience dramatic decreases in MS symptoms in their third trimesters when estrogen levels are high. After pregnancy, estrogen levels decline in the mother and the effects of MS resume.
Tiwari-Woodruff noted “This readily suggests that estrogen could be given to MS patients, except that high levels of estrogen are linked to breast and uterine cancers. Further, men would largely be reluctant to take estrogen due to its feminizing effects.”